1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sailong Pharmaceutical Group Co., Ltd. Class A

Sailong Pharmaceutical Group Co., Ltd. Class A

SSZSE:002898
0.37
CNY
-0.01
(-2.63%)
-0.58EPS
2.03BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.89
1.51
1.88
1.94
2.55
2.48
1.67
0.69
1.4
1.5
1.77
1.5
2.95
3.45
Basic EPS, GAAP
0.39
0.24
0.5
0.46
0.45
0.35
0.16
-0.38
-0.13
-0.21
0.05
-0.19
-0.69
-0.59
Free Cash Flow per Basic Share
0.51
0.13
- -
0.21
-0.06
-0.75
-0.9
-0.36
0.02
-0.06
0.03
-0.42
-0.02
- -
Dividend per Share
0.26
0.28
0.37
0.2
0.1
0.09
0.19
0.07
0.04
0.05
0.03
0.05
0.04
0.03
Book Value per Share
19.14
24.02
1.62
1.93
3.51
3.77
3.74
3.34
3.2
2.99
3.04
2.84
2.16
2.11
Tangible Book Value per Share
18.48
15.55
1.25
1.57
3.22
3.43
3.21
2.78
2.61
2.4
2.4
2.13
1.56
1.52
Basic Weighted Avg Shares
117
118
126
132
143
176
176
176
176
176
176
176
176
176
Sales/Revenue/Turnover
221
178
237
256
364
436
293
121
247
264
311
264
519
608
Operating Margin (%)
37.11
15.68
29.1
27.04
21.15
16.8
11.24
-60.95
-6.74
-9.9
3.75
-2.9
-3.95
-0.47
Depreciation Expense
4
5
6
8
10
14
20
29
33
34
33
34
54
- -
Net Income, GAAP
46
28
63
61
65
61
27
-67
-23
-37
10
-33
-121
-105
Effective Tax Rate (%)
30.09
10.43
22.31
13.35
15.66
12.99
14.72
- -
- -
- -
57.36
- -
- -
- -
Profit Margin (%)
20.73
15.83
26.66
23.94
17.71
13.96
9.37
-55.7
-9.45
-14.12
3.07
-12.58
-23.36
-17.2
Working Capital
59
54
87
84
364
278
148
51
23
-42
29
-5
-66
-66
LT Debt
- -
- -
- -
- -
- -
- -
- -
30
43
13
25
30
14
12
Total Equity
112
141
213
254
619
664
659
587
564
526
536
499
384
378
Return on Invested Capital (%)
- -
15.74
27.25
22.9
14.29
9.35
3.94
- -
- -
- -
1.44
- -
- -
- -
Return on Capital (%)
- -
20.3
34.97
25.62
14.63
9.42
4.1
- -
- -
- -
1.86
- -
- -
- -
Return on Common Equity (%)
- -
22.33
35.8
26.19
14.78
9.5
4.16
-10.79
-4.06
-6.85
1.8
-6.4
-27.56
-24.02

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Mar'26
ST Debt
152
115
103
LT Borrowings
9
8
8
LT Finance Leases
- -
6
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
176
176
176
Market Capitalization
2,013
2,397
2,028

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Mar'26
Total Current Assets
211
345
374
Cash, Cash Equivalents & STI
7
61
29
Accounts Receivable, Net
91
94
86
Inventories
88
80
111
Total Current Liabilities
243
410
441
Payables & Accruals
- -
- -
- -
ST Debt
152
115
103
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.94%
-7.74%
-23.06%
Free Cash Flow
1,248.36%
-446.52%
-94.16%
Net Income, GAAP
-71.61%
-62.62%
265.57%
Sales/Revenue/Turnover
18.92%
42.18%
96.82%
Total Cash Common Dividend
-6.91%
-6.35%
-25.45%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
69
87
63
45
264
2025
54
82
- -
319
519
2026
153
- -
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
-0.03
-0.17
-0.19
2025
-0.01
-0.08
- -
-0.46
-0.69
2026
-0.05
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.03
0.01
0.01
0.05
2025
0.01
0.01
- -
0.01
0.04
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chi Nong Cai
Full Time Employees
418
Sector
Health technology
Industry
Pharmaceuticals: major
Address
21F, Unit 2, No. 31 Zhuhai China 519060
IPO Date
Sep 12, 2017
Website
sailong.cn
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sailong Pharmaceutical Group Co., Ltd. engages in the research, development, manufacturing, and commercialization of pharmaceutical raw materials, intermediates, and prepared medicines across China. The company's diverse product portfolio features key offerings such as esomeprazole sodium, ornithine aspartate, argatroban, and milrinone, alongside a recently approved chest pain injection, injectable Nicorandil. Their therapeutic focus spans critical health areas including cardiovascular, cerebrovascular, nervous system, and digestive disorders, in addition to anti-infective, anti-bleeding, and analgesic applications. Founded in 2002, this high-tech enterprise centers its operations in Zhuhai, China, emphasizing technological innovation in its product development and nationwide sales network.